<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083160</url>
  </required_header>
  <id_info>
    <org_study_id>P10-604</org_study_id>
    <nct_id>NCT01083160</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use</brief_title>
  <acronym>FALLA</acronym>
  <official_title>Clinical Outcomes,Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab. A Multicenter Post-Marketing Observational Study in Routine Clinical Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, post marketing observational study in adult patients with
      active rheumatoid arthritis (RA) who are discontinuing treatment due to lack of efficacy,
      intolerance or to an incomplete response with either infliximab or etanercept.

      The aim of this post-marketing observational study is to obtain data on clinical outcomes,
      compliance and tolerability to determine the effectiveness of switching from infliximab or
      etanercept to adalimumab. In this cohort, the different treatment strategies are to be
      studied in the context of the routine clinical practice in the different participating
      places.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, post marketing observational study in adult patients with
      active RA who are discontinuing treatment due to lack of efficacy, intolerance or to an
      incomplete response with either infliximab or etanercept.

      The aim of this post-marketing observational study is to obtain data on clinical outcomes,
      compliance and tolerability to determine the effectiveness of switching from infliximab or
      etanercept to Adalimumab. In this cohort, the different treatment strategies are to be
      studied in the context of the routine clinical practice in the different participating
      places.

      Study Objectives:

      Primary objective:

      To assess the effectiveness of the treatment with adalimumab in patients with rheumatoid
      arthritis (RA) that have failed or presented an incomplete response to current treatment with
      either infliximab or etanercept.

      Secondary objective:

      To evaluate the compliance and clinical tolerability with adalimumab

      Investigational Plan and Selection of Study Population:

      All patients belonging to any of the centres participating in the study that meet all the
      inclusion criteria and none of the exclusion criteria will be considered eligible.

      Patients considered eligible for the study will have to give their consent for the use and/or
      disclose of the patient's personal and/or health data. Patient's consent will be obtained
      before his/her participation in the study and will be documented in an Informed Consent Form
      approved by an Ethics Committee.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to low enrollment because inclusion criteria are obsolete.
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DAS28 (Disease Activity Score in 28 Joints)</measure>
    <time_frame>Baseline and Weeks 8,16 and 24</time_frame>
    <description>The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from &quot;very good&quot; to &quot;very bad&quot;). Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (&lt;= 2.6), Low Disease Activity (&gt;2.6 to &lt;=3.2), Moderate Disease Activity (&gt;3.2 to &lt;= 5.1) and High Disease Activity (&gt;5.1). The mean change in DAS 28 score from baseline to each visit is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tender Joint Count and Swollen Joint Count</measure>
    <time_frame>Baseline and Weeks 8,16 and 24</time_frame>
    <description>The treating physician was to clinically assess each participant at each study visit and report the number of tender and swollen joints. The mean number of painful or swollen joints for participants evaluated at each time point are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Pain in a 100mm Visual Analogue Scale (VAS 100mm)</measure>
    <time_frame>Baseline and Weeks 8,16 and 24</time_frame>
    <description>Participants assessed the severity of their pain using a 0 to 100 mm horizontal visual analogue scale (VAS). The far left end indicated no pain (0 mm) and the far right meant the worst possible pain (100 mm). Participants drew a vertical line on the horizontal scale to indicate their current level of pain at each visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Compliance and Clinical Tolerability With Adalimumab</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>To assess compliance, participants were asked at the Week 8 and Week 16 visits how many doses they had missed since their previous visit. Adverse events were collected throughout the study, from the time the participant signed the informed consent form until 30 days or 5 half-lives after the last dose of study drug. For additional information see the Reported Adverse Event section.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Non responders to other anti-TNF</arm_group_label>
    <description>Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 and &lt;75 years of age that meet the American College of Rheumatology (ACR)
             criteria for RA.

          -  Patients with active RA defined as:

               1. ≥3 tender joints and ≥3 swollen joints, or

               2. DAS 28 score &gt;3.1

          -  Patients who are discontinuing treatment with either infliximab or etanercept due to:

               1. Lack of efficacy, or

               2. Incomplete response.

          -  Patients that, in the opinion of the physician could result beneficiated with the
             locally approved treatment scheme of adalimumab

          -  Those patients who switch from infliximab or etanercept to adalimumab has been done in
             the last 60 days could be included in the study.

        Exclusion Criteria:

        The following patients will not be included in the study:

          -  Patients who have active infections.

          -  Patients with latent TB. For this protocol, evidence of latent TB infection is defined
             as an induration (not erythema) of 5 mm or greater, 48-72 hrs after placement. Any
             suggested data on the clinical history or chest x-ray.

          -  Patients participating into another study or clinical trial

          -  Any condition that according to the criteria of the participating physician represents
             an obstacle for study conduct and/or represents a potential unacceptable risk for
             patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Pozos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27882</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27883</name>
      <address>
        <city>Chihuahua</city>
        <zip>31200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27884</name>
      <address>
        <city>Culiacán Sin.</city>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27888</name>
      <address>
        <city>Guadalajara, Jal.</city>
        <zip>44320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27886</name>
      <address>
        <city>Guadalajara, Jal.</city>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27887</name>
      <address>
        <city>Guadalajara, Jal.</city>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 25943</name>
      <address>
        <city>Leon, Gto.</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27885</name>
      <address>
        <city>Mexico City,</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28059</name>
      <address>
        <city>Mexico City</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27890</name>
      <address>
        <city>Puebla, Pue.</city>
        <zip>72000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27889</name>
      <address>
        <city>Puebla, Pue.</city>
        <zip>72570</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28057</name>
      <address>
        <city>Tuxtla Gutierrez</city>
        <zip>29000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <results_first_submitted>November 23, 2011</results_first_submitted>
  <results_first_submitted_qc>November 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 2, 2012</results_first_posted>
  <last_update_submitted>January 17, 2012</last_update_submitted>
  <last_update_submitted_qc>January 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Anti-TNF</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Etanercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non Responders to Other Anti-TNF</title>
          <description>Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable Population</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non Responders to Other Anti-TNF</title>
          <description>Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.34" spread="11.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>DAS28 (Disease Activity Score in 28 Joints)</title>
        <description>The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from &quot;very good&quot; to &quot;very bad&quot;). Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (&lt;= 2.6), Low Disease Activity (&gt;2.6 to &lt;=3.2), Moderate Disease Activity (&gt;3.2 to &lt;= 5.1) and High Disease Activity (&gt;5.1). The mean change in DAS 28 score from baseline to each visit is presented.</description>
        <time_frame>Baseline and Weeks 8,16 and 24</time_frame>
        <population>Analysis conducted in participants with results at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders to Other Anti-TNF</title>
            <description>Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28 (Disease Activity Score in 28 Joints)</title>
          <description>The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from &quot;very good&quot; to &quot;very bad&quot;). Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (&lt;= 2.6), Low Disease Activity (&gt;2.6 to &lt;=3.2), Moderate Disease Activity (&gt;3.2 to &lt;= 5.1) and High Disease Activity (&gt;5.1). The mean change in DAS 28 score from baseline to each visit is presented.</description>
          <population>Analysis conducted in participants with results at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS 28 at Baseline (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS 28 at Week 8 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS 28 at Week 16 (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS 28 at Week 24 (n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tender Joint Count and Swollen Joint Count</title>
        <description>The treating physician was to clinically assess each participant at each study visit and report the number of tender and swollen joints. The mean number of painful or swollen joints for participants evaluated at each time point are presented.</description>
        <time_frame>Baseline and Weeks 8,16 and 24</time_frame>
        <population>Analysis conducted in participants with results at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders to Other Anti-TNF</title>
            <description>Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joint Count and Swollen Joint Count</title>
          <description>The treating physician was to clinically assess each participant at each study visit and report the number of tender and swollen joints. The mean number of painful or swollen joints for participants evaluated at each time point are presented.</description>
          <population>Analysis conducted in participants with results at each time point.</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tender joints at Baseline (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.05" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; Week 8 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.16" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Week 16 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.44" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Week 24 (n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen joints at Baseline (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Week 8 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Week 16 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Week 24 (n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severity of Pain in a 100mm Visual Analogue Scale (VAS 100mm)</title>
        <description>Participants assessed the severity of their pain using a 0 to 100 mm horizontal visual analogue scale (VAS). The far left end indicated no pain (0 mm) and the far right meant the worst possible pain (100 mm). Participants drew a vertical line on the horizontal scale to indicate their current level of pain at each visit.</description>
        <time_frame>Baseline and Weeks 8,16 and 24</time_frame>
        <population>Analysis conducted in participants with results at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders to Other Anti-TNF</title>
            <description>Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Pain in a 100mm Visual Analogue Scale (VAS 100mm)</title>
          <description>Participants assessed the severity of their pain using a 0 to 100 mm horizontal visual analogue scale (VAS). The far left end indicated no pain (0 mm) and the far right meant the worst possible pain (100 mm). Participants drew a vertical line on the horizontal scale to indicate their current level of pain at each visit.</description>
          <population>Analysis conducted in participants with results at each time point.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS at Baseline (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.88" spread="22.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Week 8 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.69" spread="25.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Week 16 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.35" spread="26.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Week 24 (n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.70" spread="23.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Compliance and Clinical Tolerability With Adalimumab</title>
        <description>To assess compliance, participants were asked at the Week 8 and Week 16 visits how many doses they had missed since their previous visit. Adverse events were collected throughout the study, from the time the participant signed the informed consent form until 30 days or 5 half-lives after the last dose of study drug. For additional information see the Reported Adverse Event section.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Analysis population included all participants enrolled in the study who took at least one dose of adalimumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders to Other Anti-TNF</title>
            <description>Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Compliance and Clinical Tolerability With Adalimumab</title>
          <description>To assess compliance, participants were asked at the Week 8 and Week 16 visits how many doses they had missed since their previous visit. Adverse events were collected throughout the study, from the time the participant signed the informed consent form until 30 days or 5 half-lives after the last dose of study drug. For additional information see the Reported Adverse Event section.</description>
          <population>Analysis population included all participants enrolled in the study who took at least one dose of adalimumab.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reported 1 missed dose at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported 2 missed doses at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported 2 missed doses at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported 3 missed doses at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Experienced a non-serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Experienced a serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of study participation was 24 weeks. Adverse events were collected from the time the participant signed the informed consent form until 30 days or 5 half-lives following the intake of the last dose of physician-prescribed treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Non Responders to Other Anti-TNF</title>
          <description>Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>rectal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Phosphenes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Swelling in administration site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Rhinorrea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

